263 related articles for article (PubMed ID: 26109846)
1. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
2. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
3. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
[TBL] [Abstract][Full Text] [Related]
4. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
5. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
6. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records.
Jeong E; Su Y; Li L; Chen Y
J Biomed Inform; 2024 May; 153():104639. PubMed ID: 38583580
[TBL] [Abstract][Full Text] [Related]
7. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
Zhu H; Wu M
Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
[TBL] [Abstract][Full Text] [Related]
8. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
Zhao D; Long X; Wang J
Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
[TBL] [Abstract][Full Text] [Related]
9. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
Battini V; Carnovale C; Clementi E; Sessa M
Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
[TBL] [Abstract][Full Text] [Related]
10. Association of non-steroidal anti-inflammatory drug use with encephalopathy development: An analysis using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases.
Kawada K; Ishida T; Yoshioka T; Fukuda H; Hayashi T; Goda M; Ishizawa K
Pharmazie; 2024 Jun; 79(6):118-123. PubMed ID: 38877682
[TBL] [Abstract][Full Text] [Related]
11. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
12. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
13. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
[TBL] [Abstract][Full Text] [Related]
15. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.
Ang PS; Chen Z; Chan CL; Tai BC
Expert Opin Drug Saf; 2016 May; 15(5):583-90. PubMed ID: 26996192
[TBL] [Abstract][Full Text] [Related]
16. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
17. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
18. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
19. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
[TBL] [Abstract][Full Text] [Related]
20. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
